Zti Bio
1 known investors
South Korean biotech developing next-generation therapeutic radiopharmaceuticals for intractable and recurrent solid cancers.
Also known as ZTI Bio · ZTI Biosciences · Zti Biosciences Co., Ltd.
Investors · 1
Company profile
researched Aug 2026Zti Biosciences Co., Ltd. (ZTI Bio) is a South Korean drug development company established on 19 February 2020 and headquartered in Seoul. The company combines proprietary nanotechnology with biotechnology to develop next-generation therapeutic radiopharmaceuticals aimed at difficult-to-treat and recurrent solid tumors. Its stated goals include broadening the use of radioisotopes, standardizing radiopharmaceutical products and addressing multiple indications in intractable oncology.
The company's disclosed pipeline consists of two preclinical assets, ZhyperPrime and Mag-I, both directed at neoplasms. Its work is categorized around therapeutic radiopharmaceuticals and radiolabeled antibodies. Company records list Jaden Hyungseok Chang (also rendered Jang) as CEO, alongside a general director and a GMP director.
Traction
Two preclinical programs, ZhyperPrime and Mag-I, both targeting neoplasms, with no candidate reported beyond preclinical stage as of May 2025.
Latest developments
In April 2024 the company was announced as a finalist for the Life Sciences Innovation Summit 2024, held on the sidelines of Abu Dhabi Global Healthcare Week in May 2024. Its pipeline profile was last updated in May 2025 with both programs at preclinical stage.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
An early-stage radiopharmaceutical developer in South Korea with a preclinical-stage pipeline; recognized internationally as one of 11 finalists selected from more than 150 applicants across over 20 countries for the 2024 J.P. Morgan Life Sciences Innovation Summit.
Technology
ZTI Bio's core technology is TERACARRIER, a nanotechnology-based delivery platform intended to carry radioisotopes for therapeutic use. The approach merges nanotechnology with biotechnology to produce therapeutic radiopharmaceuticals and radiolabeled antibodies.
Go-to-market
Patients with intractable, recurrent and difficult-to-treat solid tumors, addressed through oncology clinical development.
Geography
Headquartered in Seoul, South Korea, with a listed address in Yuseong-gu, Daejeon; participated in an industry summit in Abu Dhabi, UAE.
History
The company was established on 19 February 2020 and is based in Seoul, South Korea, with an address also listed at Gwahak-ro, Yuseong-gu, Daejeon. By 2024 it had advanced two preclinical oncology candidates and was selected as a finalist in the inaugural J.P. Morgan Life Sciences Innovation Summit held in Abu Dhabi in May 2024.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsZTI Biosciences, represented by CEO Jaden Hyungseok Chang, PhD, was named one of 11 finalists for the inaugural Life Sciences Innovation Summit 2024, announced by J.P. Morgan Asset Management's Life Sciences Private Capital, Blue Horizon Advisors and United AlSaqer Group ahead of Abu Dhabi Global Healthcare Week. Finalists were selected from more than 150 applications across over 20 countries; the summit took place 14-15 May 2024.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- Zti Biosciences Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapsesynapse.patsnap.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Zti Bio do?
- South Korean biotech developing next-generation therapeutic radiopharmaceuticals for intractable and recurrent solid cancers.
- Who are Zti Bio's investors?
- Zti Bio's investors include Kiwoom Investment.